H.R. 5671: Colorectal Cancer Payment Fairness Act

This bill, known as the Colorectal Cancer Payment Fairness Act, proposes amendments to the Social Security Act concerning how colorectal cancer screenings are funded under the Medicare program. The key provisions of the bill are as follows:

Elimination of Coinsurance Requirement

The bill aims to eliminate the coinsurance requirement for certain colorectal cancer screening tests provided to Medicare beneficiaries. Currently, under Medicare policy, patients are required to share a portion of the costs for various medical services, known as coinsurance. By removing this requirement for specific screening tests, the bill would mean that patients would not have to pay out-of-pocket costs for these screenings.

Specific Amendments

• The bill proposes to remove the existing time limit that coinsurance was to be eliminated only until January 1, 2030.
• Furthermore, it revises the coverage percentage for colorectal cancer screenings from 85% to 100% for each year thereafter, effectively increasing the full coverage that Medicare beneficiaries would receive.
• Additionally, it aims to remove outdated provisions within the current statute that are no longer relevant to the updated funding framework proposed by the bill.

Impact on Medicare Beneficiaries

By eliminating the coinsurance requirement, the bill is designed to facilitate greater access to colorectal cancer screening tests for Medicare beneficiaries. This could potentially lead to an increase in the number of individuals participating in these preventive screenings, which are crucial for early detection and treatment of colorectal cancer.

Context and Purpose

The overarching goal of this legislation is to improve health outcomes through increased access to colorectal cancer screenings by removing financial barriers for Medicare recipients. Colorectal cancer is a significant health issue, and making screenings more affordable is intended to encourage early detection and ultimately reduce morbidity and mortality associated with the disease.

Relevant Companies

None found